资讯

AFN9 小时
BiomEdit raises $18.4m Series B to expand designer probiotics platform
BiomEdit has raised an $18.4m Series B round and is gearing up to launch its first product, a designer probiotic to tackle ...
PipelineReview.com8 小时
Update on CARES Phase III clinical programme of anselamimab in light chain amyloidosis
The CARES clinical programme is the largest prospective investigation in cardiac AL amyloidosis to date with a total of 406 patients enrolled from 19 countries globally, including 281 patients with ...